Are You a Patient?

Welcome to Endorenew. If you are living with Asherman syndrome or thin endometrium, you might be looking for answers. We are here to help you understand your condition and explore new possibilities.

Understanding the Condition

What is Asherman Syndrome?

Asherman syndrome is characterized by intrauterine adhesions (scar tissue) that partially or completely block the uterine cavity.

It often develops after:

Uterine surgery
Dilation & Curettage (D&C)
Postpartum complications
Infection

These adhesions damage the basal layer of the endometrium, limiting its ability to regenerate properly during each menstrual cycle.

In moderate to severe cases, adhesions may recur even after surgical removal.

What is Thin Endometrium?

A thin endometrium refers to insufficient thickening of the uterine lining during the menstrual cycle.

In fertility contexts, it typically means an endometrial thickness below what is considered optimal for implantation (generally <7 mm measured by transvaginal ultrasound around ovulation or embryo transfer).

It may be associated with:

Hormonal imbalance
Previous uterine surgery
Repeated curettage procedures
Long-term damage to the basal layer
Age-related changes

Even with hormonal stimulation, some women are unable to achieve adequate endometrial thickness — even when embryos are healthy.

Why Current Treatments May Not Be Enough

Standard treatments include:

Hysteroscopic removal of adhesions
Hormonal therapies to stimulate endometrial growth
Intrauterine devices or barrier methods to prevent recurrence

While these approaches may temporarily improve structure, they often do not restore the biological regenerative capacity of the endometrium.

Recurrence remains common.
Full functional recovery is not always achieved.

A Regenerative Approach

Introducing PAULA Cell Therapy

PAULA (Patient AUtologous endometriaL Advanced) Cell Therapy is a regenerative treatment developed for women with severe endometrial damage who have not responded to conventional therapies.

It is based on the use of autologous CD133+ stem cells, derived from your own body and administered under a structured clinical protocol.

Rather than focusing only on removing adhesions or stimulating growth, PAULA Therapy aims to:

Promote new blood vessel formation
Support tissue repair
Restore endometrial thickness
Improve uterine receptivity

The goal is to rebuild biological function — not just correct structure.

Who May Be a Candidate?

You may be eligible if you have:

Moderate to severe Asherman syndrome
Persistent thin endometrium unresponsive to treatment
Repeated implantation failure or pregnancy loss linked to these conditions

Your fertility specialist can help determine whether PAULA Therapy may be appropriate in your case.

A Recognized and Regulated Innovation

PAULA Cell Therapy has received:

Orphan Drug Designation from the European Medicines Agency (EMA) for Asherman syndrome
Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) for thin endometrium

These recognitions support its development as a novel treatment addressing unmet medical needs in reproductive medicine.

Why consider PAULA Therapy?

PAULA Therapy:

Is an Advanced Therapy Medicinal Product (ATMP) based on autologous somatic cell therapy
Is developed under strict scientific and regulatory standards
Has shown encouraging clinical results in improving endometrial thickness and uterine health
Represents a pioneering regenerative approach in reproductive medicine